Nestlé Health Science acquires Pamlab

Specialty biomedical company Pamlab has signed an agreement to sell its business to Nestlé Health Science for an undisclosed amount. Nestlé Health Science aims to develop science-based nutritional solutions to deliver improved personalised healthcare for people with chronic medical conditions.

Pamlab’s products, including Metanx, CerefolinNAC and Deplin, have helped address the nutritional management of metabolic issues associated with diabetic peripheral neuropathy, mild cognitive impairment and clinical depression respectively, and other diseases and conditions.

“The acquisition of the Pamlab business is aligned with our strategic ambition to provide science-based nutritional solutions for people with chronic medical conditions,” said Luis Cantarell, Nestlé Health Science President and CEO.

“Pamlab will particularly strengthen our brain health platform and provide us an additional foothold in metabolic health in the US. By leveraging our nutrition heritage and US operations with Pamlab’s proven expertise in medical foods and strong salesforce capabilities, together we can play a key role in helping to manage certain chronic diseases and improve the quality of patients’ lives.”

Nestlé Health Science anticipates it will be able to leverage Pamlab’s strong sales-force capabilities and reach to promote science-based personalised nutritional solutions in the US.